Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Alzheimer’s disease and related dementias

Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.

Stephen S Dominy; Casey Lynch; Florian Ermini; Malgorzata Benedyk; Agata Marczyk; Andrei Konradi; Mai Nguyen; Ursula Haditsch; Ursula Haditsch; Debasish Raha; Christina Griffin; Leslie J Holsinger; Shirin Arastu-Kapur; Samer Kaba; Alexander Lee; Mark I Ryder; Barbara Potempa; Piotr Mydel; Annelie Hellvard; Karina Adamowicz; Hatice Hasturk; Glenn D Walker; Eric C Reynolds; Richard L M Faull; Maurice A Curtis; Mike Dragunow; Jan Potempa

Originally published in Science advances · 2019-01-23

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Porphyromonas gingivalis , the keystone pathogen in chronic periodontitis, was identified in the brain of Alzheimer's disease patients. Toxic proteases from the bacterium called gingipains were also identified in the brain of Alzheimer's patients, and levels correlated with tau and ubiquitin pathology. Oral P. gingivalis infection in mice resulted in brain colonization and increased production of Aβ 1-42 , a component of amyloid plaques. Further, gingipains were neurotoxic in vivo and in vitro, exerting detrimental effects on tau, a protein needed for normal neuronal function. To block this neurotoxicity, we designed and synthesized small-molecule inhibitors targeting gingipains. Gingipain inhibition reduced the bacterial load of an established P. gingivalis brain infection, blocked Aβ 1-42 production, reduced neuroinflammation, and rescued neurons in the hippocampus. These data suggest that gingipain inhibitors could be valuable for treating P. gingivalis brain colonization and neurodegeneration in Alzheimer's disease.

DISCUSSION

The findings of this study offer evidence that P. gingivalis and gingipains in the brain play a central role in the pathogenesis of AD, providing a new conceptual framework for disease treatment. Accordingly, we demonstrate the presence of P. gingivalis DNA and gingipain antigens in AD brains and show in vivo that oral administration of small-molecule gingipain inhibitors blocks gingipain-induced neurodegeneration, significantly reduces P. gingivalis load in the mouse brain, and significantly decreases the host Aβ1–42 response to P. gingivalis brain infection.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?